Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.

Kanis, J A; Barton, I P; Johnell, O

Kanis, J A; Barton, I P; Johnell, O.

Affiliation

Kanis JA; Centre for Metabolic Bone Diseases (WHO Collaborating Centre), University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK. w.j.pontefract@sheffield.ac.uk

Osteoporos Int ; 16(5): 475-82, 2005 May.

Article in En | MEDLINE | ID: mdl-15875093

Subject(s)

Etidronic Acid/analogs & derivatives; Etidronic Acid/therapeutic use; Osteoporosis, Postmenopausal/complications; Spinal Fractures/prevention & control; Absorptiometry, Photon; Aged; Anthropometry; Bone Density; Double-Blind Method; Female; Femur Neck/physiopathology; Humans; Lumbar Vertebrae/physiopathology; Middle Aged; Recurrence; Risedronic Acid; Risk Factors; Spinal Fractures/etiology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Osteoporosis, Postmenopausal / Spinal Fractures / Etidronic Acid Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Middle aged Language: En Journal: Osteoporos Int Journal subject: METABOLISMO / ORTOPEDIA Year: 2005 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links